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Summary
Colorectal cancer (CRC) is one of the most common cancers and one of the leading causes 
of cancer death in the Western world. The disease arises from the accumulation of mutations in 
oncogenes, tumor suppressor genes and mismatch repair genes during progression from normal 
colon epithelium to adenoma and metastatic carcinoma. Improved understanding of genetic 
events that underline tumor development and progression may contribute to new strategies for 
prevention, diagnosis as well as for therapy. The results of Human genome project showed that 
each person has its unique genetic “signature” as a consequence of a large number of inherited 
genetic variations. There are also sporadic molecular changes specific for each tumor type. This 
mini review will give some information about the most frequent molecular genetics changes in 
colorectal cancer and its molecular stratification due to its heredity, germline pharmacogenetic 
markers, somatic mutations and microsatellite instability.
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Colorectal cancer (CRC) is one of the most common cancers and represents the 
third most diagnosed cancer in both men and women. Despite advances in surgery, 
chemotherapy and screening it is still one of the leading causes of cancer related 
death in the Western world [1].
Of all human cancers, the molecular genetic alterations in colorectal cancer are 
best understood. The disease arises from the accumulation of mutations in oncoge-
nes, tumor suppressor genes and mismatch repair (MMR) genes during progression 
from normal colon epithelium to adenoma and metastatic carcinoma (Figure 1) [2].
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The majority of colon cancers (80%) arise in sporadic form and only 20% of the 
patients have a family history of CRC. However, only 5-6% of CRC arise from a 
germline mutation in high penetrant genes, adenomatous polyposis coli (APC) gene 
(1%) and MMR genes (5%) while the remaining CRCs have a positive family history 
but cannot be categorized to any hereditary CRC syndrome. These familial CRC 
are caused by single nucleotide polymorphisms (SNP) in less penetrant genes such 
as cytokines. Many susceptibility loci have been identified, however, their value in 
CRC risk prediction remains low [3,4].
The development of colorectal cancer is a multistep process caused by progre-
ssive accumulation of genetic and epigenetic changes that cause activation of on-
cogenes and/or inactivation of tumor suppressor genes. The earliest trigger is the 
mutation of the APC (adenomatous polyposis coli) gene. Mutations in oncogenes 
(KRAS) and other tumor suppressor genes (p53, DPC4) drive tumor towards mali-
gnant transformation and metastasis. Alongside with gene mutations, deregulated 
expression of oncogenes and/or tumor suppressor genes can also occur as a con-
sequence of epigenetic modifications of their promoters [3,5-7].
Figure 1. Multistep model of colorectal cancer tumorigenesis.
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Improved understanding of genetic events that underline tumor development, 
progression and metastasis may contribute to new strategies for prevention, scree-
ning, diagnosis as well as for therapy. Survival of patients with metastatic colorectal 
cancer has improved over the past several decades, due to the development of new 
combinations of standard chemotherapy such as 5-fluorouracil (5-FU), irinotecan, 
and oxaliplatin, as well as to the introduction of new targeted therapies. Among the 
available targeted therapies are monoclonal antibodies that target the epidermal 
growth factor receptor (EGFR) which have clearly demonstrated efficacy in the tre-
atment of metastatic CRC [8,9].
Individual patient response to therapy could be very diverse, even if their di-
sease seems similar when evaluating clinicopathological parameters. Many drugs 
commonly used in clinical practice show interindividual variations in efficacy, dose 
requirements as well as the presence of side effects. There is increasing evidence that 
treatment response is based on the genetic “signature” of the individuals as well as 
on the molecular changes in the tumor itself. Pharmacogenetics is the field of perso-
nalized medicine that examines the impact of genetic variations on the individual 
response to drug treatment. These variations are often due to germ line mutations in 
genes that encode for drug metabolizing enzymes, transporters, cellular targets and 
signaling pathway. For example, patients with variant DPYD*2A in dihydropyri-
midine dehydrogenase (DPD) gene are at high risk to develop severe 5-FU toxicity 
as well as patients with a variant UGT1A1*28 in uridine diphosphat-glucuronosyl 
transferase 1A1 (UGT1A1) gene are at a higher risk of developing neutropenia and 
diarrhea when treated with irinotecan for CRC. Knowledge about the influence of 
these variations on drug response can be used to identify, through pretreatment 
genetic screening, the patients who will be responders to a specific drug and those 
at greater risk to develop an adverse drug reaction [10-13].
An important distinction between pharmacogenetics in oncology and other the-
rapeutics fields is that somatic mutations, frequently acquired in cancer tissues, also 
contribute to the variations in treatment outcome, sensitivity or resistance to cancer 
therapy [13,14].
The epidermal growth factor receptor (EGFR) signaling pathway plays an im-
portant role in normal cells as well as in tumorigenesis. EGFR also represents an im-
portant target for cancer treatment because its activation stimulates key processes 
involved in tumor growth and progression, including proliferation, angiogenesis, 
invasion, metastasis, and drug sensitivity (Figure 2) [8,15,16].
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Figure 2. Epidermal growth factor receptor (EGFR) signaling pathway.
Novel therapeutic agents, anti-EGFR monoclonal antibodies, have been shown 
to be effective therapies for patients with metastatic CRC, but only in a small pro-
portion of patients [15]. Alterations within the EGFR signaling cascade, such as gene 
mutations in its downstream regulators, have been shown to contribute to colorectal 
carcinogenesis, but are also predictive biomarkers of anti-EGFR therapy. Genetic 
analyses showed that the presence of somatic mutations in the KRAS, found in 40-
60% of CRC, can predict lack of response and resistance to anti-EGFR antibodies in 
patients with metastatic CRC [16].
KRAS mutations, most commonly codon 12/13 missense mutations, lead to con-
stitutive activation of the KRAS protein. Because KRAS is the downstream effector 
of EGFR, activating mutations in the KRAS gene lead to an independent activation 
of the downstream signal transduction. This unregulated downstream signaling 
will not be blocked by antibodies that target the EGFR receptor and KRAS mutation 
status is a strong predictive marker of resistance to EGFR targeted therapy [17]. Un-
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fortunately at least 60% of patients with wild type KRAS gene will still not respond 
to anti-EGFR therapies, suggesting the need for additional biomarkers to help dis-
tinguished responders from no responders [17,18]
The BRAF gene encodes a serine-threonine protein kinase that is downstream 
of KRAS in the MAPK signaling pathway and mutations in these two genes are 
mutually exclusive. BRAF mutations occur in 5-22% of all colorectal cancers, and in 
40-52% of CRC with microsatellite instability [19,20]. Analysis for mutations in both 
genes could identify as many as 40% of patients who have no chance of responding 
to this class of drugs. Retrospective studies suggest that concomitant detection of 
KRAS and BRAF mutations, combined with detection of mutations in two other 
genes (PIK3CA and PTEN), can identify up to 70% of patients who are unlikely to 
respond to anti-EGFR therapies [18].
Lynch syndrome (LS) is a dominantly inherited cancer syndrome in which pre-
disposition to colorectal, endometrial, gastric and other cancers occurs due to the 
mutations in MMR genes. Mismatch repair proteins form a complex that detects 
and corrects replication errors. A deregulated MMR system due to the mutations in 
MMR genes leads to accelerated accumulation of somatic mutations, often resulting 
in carcinogenesis. The most frequently mutated MMR genes are MSH2 and MLH1, 
in 70-90% of Lynch syndrome, with the remaining 10-30% distributed equally in 
MSH6 and PMS2 [21].
Microsatellite instability (MSI) is the molecular marker of MMR genes muta-
tions and DNA mismatch repair deficiency. Since its initial description in heredi-
tary colorectal cancer in 1993 and its association with Lynch syndrome, the most 
common inherited cancer predisposition syndrome, new results suggests that MSI 
status may also be of prognostic and predictive biomarker in the management of 
sporadic CRC. To examine the presence of MSI in a CRC tumor the National Cancer 
Institute (NCI) workshop (1997) recommended to analyze a panel of five microsa-
tellites including two mononucleotide (BAT25, BAT26) and three dinucleotide mar-
kers (D2S123, D5S346 and D17S250), (Figure 3), [22,23]. Depending on the number of 
microsatellite markers displaying additional alleles, MSI can be rated as MSI-high 
(MSI-H, >2 out of 5 markers), MSI-low (MSI-L, 1 out of 5), or microsatellite stable 
(MSS, 0 out of 5). MSI-H status could be finding in the most cases of LS colorectal 
tumors but also in 15% of sporadic CRC [24]. Most of these tumors also exhibit loss 
of MLH1 protein expression as a consequence of the epigenetic silencing of MLH1 
gene promoter. Recent findings demonstrated that inactivation of the MMR system 
with MSI-H status and MLH1 protein negative tumors in hereditary as well as in 
sporadic CRC tumors can result in resistance to 5-FU treatment and could be used 
as valuable pharmacogenetic marker [25].
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Figure 3. Analysis of microsatellite instability (MSI-high tumor). A. Blood; 
B. Normal tissue adjcent to tumor; C. Tumor tissue.
Clinicians have long known that each patient and their disease are unique. Re-
cent advances in molecular medicine have enabled a more detailed understanding 
of the impact of genetics in disease development and progression. Each individual 
cancer as well as colorectal cancer has a set of molecular alterations that can be de-
fined as the genetic “signature” of that particular tumor. Recent genomic analyses 
of different human tumors confirmed that individual tumors exhibit heterogeneous 
patterns of somatic mutations, gene amplifications and deletions, epigenetic profi-
les, and gene expression profiles. Modern molecular platforms give the ability to 
characterize tumors at multiple levels and to define biological subtypes of cancer. 
Cancers could be divided into subtypes that are more or less aggressive. Identifica-
tion of a more aggressive subtype may influence the type of their treatment. Mo-
lecular stratification and sub classification of tumors will add a step to traditional 
clinical practice and better diagnosis and therapy of different types of cancer as well 
as colorectal cancer [26,27].
As more biomarkers will be identified and validated predicting testing will be 
used more extensively in clinical decision making. Optimization of tools to predict 
the risk for developing cancer, to diagnose a disease at an early stage, to give a pro-
gnosis, and predict treatment response is of great importance to the patients as well 
as to the health professionals.
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Sažetak
Molekularna stratifikacija kolorektalnog raka
Kolorektalni karcinom je jedan od najčešćih zloćudnih tumora i jedan od vodećih uzroka 
smrti od raka u zemljama razvijenog svijeta. Oboljenje nastaje kroz duži niz godina tijekom kojih 
kao posljedica mutacija u onkogenima, tumor supresorskim genima i genima za popravak DNA 
iz normalne sluznice kolona preko adenoma nastaje zloćudni invazivni karcinom. Dobro pozna-
vanje molekularne podloge nastanka i napredovanja kolorektalnog karcinoma doprinosi boljoj 
prevenciji, ranoj dijagnostici i uspješnijoj terapiji ovog zloćudnog tumora. Rezultati istraživanja 
u području molekularne patologije raka ukazuju na to da svaki tumor posjeduje svoj vlastiti ge-
netski otisak koji je rezultat individualnih, za taj tumor specifičnih, molekularnih promjena ali i 
genetičkih karakteristika oboljele osobe. U ovom kratkom preglednom radu opisane su najčešće 
molekularno genetičke promjene u kolorektalnom karcinomu te molekularna stratifikacija ovog 
zloćudnog tumora s obzirom na nasljednost, farmakogenetske biljege, stečene mutacije i mikro-
satelitnu nestabilnost.
Ključne riječi: kolorektalni rak; biomarkeri; molekularna stratifikacija.
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